Last reviewed · How we verify
Chemotherapy by Investigator's choice
Chemotherapy by Investigator's choice is a Small molecule drug developed by AIO-Studien-gGmbH. It is currently in Phase 2 development. Also known as: FLO regimen, - Oxaliplatin 85 mg/m², - Leucovorin 200 mg/m², - 5-Fluorouracil 2600 mg/m².
At a glance
| Generic name | Chemotherapy by Investigator's choice |
|---|---|
| Also known as | FLO regimen, - Oxaliplatin 85 mg/m², - Leucovorin 200 mg/m², - 5-Fluorouracil 2600 mg/m², mod. FOLFOX-6 regimen |
| Sponsor | AIO-Studien-gGmbH |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma (PHASE3)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Fulzerasib Sequential Sintilimab Plus Platinum-Doublet Neoadjuvant Therapy for Resectable KRAS G12C-Mutant NSCLC (PHASE2)
- Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (PHASE3)
- Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma (PHASE3)
- A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer (PHASE3)
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy by Investigator's choice CI brief — competitive landscape report
- Chemotherapy by Investigator's choice updates RSS · CI watch RSS
- AIO-Studien-gGmbH portfolio CI
Frequently asked questions about Chemotherapy by Investigator's choice
What is Chemotherapy by Investigator's choice?
Chemotherapy by Investigator's choice is a Small molecule drug developed by AIO-Studien-gGmbH.
Who makes Chemotherapy by Investigator's choice?
Chemotherapy by Investigator's choice is developed by AIO-Studien-gGmbH (see full AIO-Studien-gGmbH pipeline at /company/aio-studien-ggmbh).
Is Chemotherapy by Investigator's choice also known as anything else?
Chemotherapy by Investigator's choice is also known as FLO regimen, - Oxaliplatin 85 mg/m², - Leucovorin 200 mg/m², - 5-Fluorouracil 2600 mg/m², mod. FOLFOX-6 regimen.
What development phase is Chemotherapy by Investigator's choice in?
Chemotherapy by Investigator's choice is in Phase 2.
Related
- Manufacturer: AIO-Studien-gGmbH — full pipeline
- Also known as: FLO regimen, - Oxaliplatin 85 mg/m², - Leucovorin 200 mg/m², - 5-Fluorouracil 2600 mg/m², mod. FOLFOX-6 regimen
- Compare: Chemotherapy by Investigator's choice vs similar drugs
- Pricing: Chemotherapy by Investigator's choice cost, discount & access